Nord/LB set a €100.00 ($117.65) price objective on Merck KGaA (FRA:MRK) in a research note issued to investors on Thursday, August 3rd. The firm currently has a neutral rating on the healthcare company’s stock.
A number of other equities analysts have also recently commented on MRK. Commerzbank Ag set a €109.00 ($128.24) price target on Merck KGaA and gave the stock a neutral rating in a research note on Thursday, August 3rd. Warburg Research set a €116.00 ($136.47) target price on Merck KGaA and gave the company a neutral rating in a research note on Thursday, August 3rd. Morgan Stanley set a €103.00 ($121.18) target price on Merck KGaA and gave the company a neutral rating in a research note on Monday, May 22nd. Deutsche Bank AG set a €106.00 ($124.71) target price on Merck KGaA and gave the company a neutral rating in a research note on Wednesday, July 26th. Finally, Berenberg Bank set a €110.00 ($129.41) target price on Merck KGaA and gave the company a neutral rating in a research note on Thursday, August 3rd. One investment analyst has rated the stock with a sell rating, fifteen have issued a hold rating and six have given a buy rating to the stock. The stock has a consensus rating of Hold and an average price target of €108.76 ($127.96).
Shares of Merck KGaA (FRA:MRK) opened at 92.995 on Thursday. The company has a market capitalization of €40.43 billion and a PE ratio of 24.243. The company has a 50-day moving average price of €99.05 and a 200 day moving average price of €103.76. Merck KGaA has a one year low of €89.00 and a one year high of €115.00.
WARNING: This story was published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this story on another publication, it was stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this story can be read at https://stocknewstimes.com/2017/08/16/merck-kgaa-mrk-given-a-100-00-price-target-at-nordlb-updated.html.
Merck KGaA Company Profile
.
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.
